Osaka, Japan

Masahiro Mineno

This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: Takeda Pharmaceutical Company Limited. Active years: 2024.

USPTO Granted Patents = 1 

% Patents Active = 100.0

 

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2024

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Masahiro Mineno: Innovator in Cationic Lipids

Introduction

Masahiro Mineno is a prominent inventor based in Osaka, Japan. He is known for his significant contributions to the field of biotechnology, particularly in the development of cationic lipids. His work focuses on enhancing the efficiency of introducing active ingredients, especially nucleic acids, into cells.

Latest Patents

Masahiro Mineno holds 1 patent related to cationic lipids. This patent provides a technique that enables the introduction of active ingredients into cells with superior efficiency. The invention includes a compound represented by a specific formula, where various parameters define the structure of the cationic lipids used in the technique.

Career Highlights

Mineno is associated with Takeda Pharmaceutical Company Limited, a leading global biopharmaceutical company. His role at Takeda has allowed him to contribute to innovative research and development in the pharmaceutical industry.

Collaborations

Throughout his career, Masahiro Mineno has collaborated with notable colleagues, including Satoru Matsumoto and Yoshimasa Omori. These collaborations have furthered advancements in the field of biotechnology and have led to significant innovations.

Conclusion

Masahiro Mineno's work in cationic lipids represents a vital advancement in biotechnology, showcasing his commitment to improving the efficiency of drug delivery systems. His contributions continue to impact the pharmaceutical industry positively.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…